GLP-1 Agonists: Addressing Side Effects of Weight Loss Drugs
17 November 2025
9:00 AM - 10:00 AM PST
Session Description
Glucagon-like peptide (GLP-1) receptor agonists like Mounjaro® and Ozempic® are being studied for a wide range of uses including for substance use disorders and neurodegenerative diseases. Speakers will discuss the extensive effects of these medications, including adverse reactions like nausea and vomiting. Researchers will highlight how GLP-1 agonists may affect other motivated behaviors beyond eating, leading to loss of muscle mass and chronic dehydration, and what this means for future research.